European Patent Office

T 0841/23 (Avelumab flat dosing/PFIZER INC.) of 07.01.2025

European Case Law Identifier
ECLI:EP:BA:2025:T084123.20250107
Date of decision
7 January 2025
Case number
T 0841/23
Online on
1 April 2025
Petition for review of
-
Application number
17784701.9
Language of proceedings
English
Distribution
No distribution (D)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
Dosing regimen of avelumab for the treatment of cancer
Applicant name
Pfizer Inc.
Merck Patent GmbH
Opponent name
-
Board
3.3.04
Headnote
-
Relevant legal provisions
Rules of procedure of the Boards of Appeal 2020 Art 013(1)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
Keywords
Amendment to appeal case - suitability of amendment to resolve issues raised (no)
Catchword
-
Cited cases
-
Citing cases
-

Order

For these reasons it is decided that:

- The appeal is dismissed